Abstract Categories

Abstract Categories 

Abstract Dates Abstract FAQsAbstract Reference Guide

Category Types

Primary Category and Subcategory

All abstract submitters will be asked to indicate the primary category and subcategory with which the abstract most closely aligns. This primary selection will aid the abstract reviewers in placing the abstract into the most appropriate session, if accepted for oral presentation. Accepted abstracts are also listed according to the primary category and subcategory selected within the JITC supplement and the Poster Hall.

Secondary Categories

Should the submitter believe more than one category is applicable, they can select a secondary category and subcategory. The secondary category and subcategory will only be used to aid the abstract reviewers in placing the abstract into the most appropriate session, if accepted for oral presentation. The secondary category and subcategory WILL NOT be used for the abstract listing in publications or placement in the Poster Hall.

Abstract Categories and Subcategories

1. Clinical Trials in Progress

  1. Skin Cancers
  2. Lung Cancers
  3. Genitourinary Cancers
  4. Breast Cancers
  5. Gynecologic Cancers
  6. Hematologic Malignancies
  7. Brain and CNS Cancers
  8. Head and Neck Cancers
  9. Gastrointestinal/GEJ/Colorectal Cancers
  10. Hepatocellular Cancer
  11. Multi-Cancer
  12. Biomarker-Defined Cancers
  13. Other

2. Clinical Trials Completed

  1. Skin Cancers
  2. Lung Cancers
  3. Genitourinary Cancers
  4. Breast Cancers
  5. Gynecologic Cancers
  6. Hematologic Malignancies
  7. Brain and CNS Cancers
  8. Head and Neck Cancers
  9. Gastrointestinal/GEJ/Colorectal Cancers
  10. Hepatocellular Cancer
  11. Multi-Cancer
  12. Biomarker-Defined Cancers
  13. Other

3. Biomarkers, Immune Monitoring and Novel Technologies

  1. Imaging
  2. Next-Generation Sequencing
  3. Neoantigen Identification and Characterization
  4. Animal Models
  5. Circulating DNA and Other Blood-Based Soluble Markers
  6. Gene Editing
  7. Bioengineering
  8. Other

4. Cellular Therapies

  1. Chimeric Antigen Receptors
  2. Non-CAR Adoptive Cell Therapies
  3. Other Cellular Therapies
  4. Response/Resistance Mechanisms
  5. Combinations
  6. Toxicity
  7. TILs
  8. Other

5. Checkpoint Blockade Therapy

  1. Response/Resistance Mechanisms
  2. Autoimmunity/Toxicity
  3. Innate Immune Checkpoints
  4. Combination Treatments (Other Immunotherapies)
  5. Combination Treatments (Chemotherapy, Radiotherapy, Targeted Therapy)
  6. Other

6. Combination Immunotherapies

  1. Immunotherapy/Immunotherapy
  2. Immunotherapy/Chemotherapy
  3. Immunotherapy/Radiotherapy
  4. Immunotherapy/Targeted Therapy
  5. Immunotherapy/Surgery
  6. Immunotherapy/Other
  7. Response/Resistance Mechanisms
  8. Toxicity
  9. Other

7. Data Sharing, Handling and Access

  1. New Data Sharing Initiatives
  2. Data Analysis Platforms
  3. Tumor Sample Libraries
  4. Genetic Data Libraries
  5. Combined Tumor Sample/Genetic Data Libraries
  6. Other

8. Education and Treatment Management

  1. Post-Immunotherapy Treatment Strategies
  2. Patient Experience and Education
  3. Clinician Education
  4. Best Practices for Cancer Immunotherapy Treatment
  5. Case Studies
  6. Other

9. Immune Cell Types and Biology

  1. Cellular Metabolism
  2. Innate Immunity
  3. Adaptive Immunity
  4. Antitumor Immunity
  5. Immunogenomics
  6. Epigenetic Regulation
  7. Immunotherapeutic Response/Resistance Mechanisms
  8. Immune Effects of Non-Immunotherapeutic Treatments
  9. Toxicity
  10. B cells
  11. T cells
  12. NK cells
  13. Dendritic cells
  14. Non-Conventional cells
  15. Macrophages
  16. Other

10. Immune-Stimulants and Immune Modulators

  1. Vaccines
  2. Cytokines
  3. Oncolytic Viruses
  4. TLR Agonists
  5. STING Agonists
  6. Intra-Tumoral Agents
  7. Immune Effects of Non-Immunotherapeutic Treatments
  8. Reponses/Resistance Mechanisms
  9. Toxicity
  10. Other

11. Immuno-Conjugates and Chimeric Molecules

  1. Antibody-Drug Conjugates
  2. Antibody-Radionuclide Conjugates
  3. Bispecific Molecules
  4. Response/Resistance Mechanisms
  5. Combination Treatments
  6. Toxicity
  7. Other

12. Immuno-Engineering

13. Immunotherapy Toxicities

  1. Toxicity Management: Clinical Care and Best Practices
  2. Mechanisms of Toxicities
  3. Long-Term Immunotherapy Toxicities
  4. Other

14. Machine Learning, Artificial Intelligence and Computational Modeling

15. Microbiome and Other Environmental Factors

  1. Immunotherapeutic Response/Resistance Mechanisms
  2. Diet, Exercise and Metabolism
  3. Gut Microbiome
  4. Tumor Microbiome
  5. Other

16. Novel Single-Agent Immunotherapies

17. Premalignancy

18. Regulatory, Financial and Access Considerations

  1. Immunotherapy Cost and Value Analyses
  2. Patient Access Initiatives
  3. Regulatory Considerations
  4. Reimbursement Initiatives
  5. Immunotherapy Clinical Trial Design
  6. Patient Exclusion/Inclusion Criteria
  7. Other

19. Tumor and Stromal Cell Biology

  1. Cellular Metabolism
  2. Oncogenetics
  3. Epigenetic Regulation
  4. Tumor Antigens and Others
  5. Virus-Driven Cancers
  6. Cancer-Associated Fibroblasts
  7. Endothelial Cells
  8. Tumor Microenvironment
  9. Mouse Models
  10. Toxicity
  11. Other

20. Other

Inclusion Enrollment Report Data Table

To assist with SITC’s commitment to improve diversity and inclusion in clinical trials, please complete the Inclusion Enrollment Report data table, which follows the NIH data template. This data will not be shared with abstract reviewers and will not be included in the publication of accepted abstracts. The data will only be accessible to SITC staff and will only be reported in aggregate. Presenters for abstracts that are accepted for a poster or oral presentation are encouraged to include this data in the presentation if applicable. Thank you for helping SITC monitor the landscape of diversity in clinical trial enrollment.  

941.jpg
941.jpg